Bellevue Emerging Markets Healthcare I2

Reference Data

ISIN LU1585228379
Valor Number
Bloomberg Global ID
Fund Name Bellevue Emerging Markets Healthcare I2
Fund Provider Bellevue Asset Management AG Zürich, Switzerland
Phone: +41 44 267 67 00
E-Mail: info@bellevue.ch
Web: www.bellevue.ch
Fund Provider Bellevue Asset Management AG
Representative in Switzerland Waystone Fund Services (Switzerland) SA
Lausanne
Phone: 0041213111781
Distributor(s) Bank am Bellevue AG
Küsnacht
Phone: +41 44 267 67 67
Asset Class Equities
EFC Category
Distribution Policy Accumulation
Home Country Luxembourg
Issuing Condition Combination of issuing commission charged by the fund management company and transaction fee charged by the fund
Redemption Condition Combination of redemption commission charged by the fund management company and transaction fee charged by the fund
Investment Strategy *** The sub-fund is an equity fund. The investment objective of sub-fund is to achieve long-term capital growth by investing at least two thirds of the net assets of the fund in a portfolio of carefully chosen shares and other equity securities of companies that have their registered office or carry out the majority of their economic activity in the healthcare markets of emerging countries.
Peculiarities

Fund Prices

Current Price * 120.57 USD 22.04.2025
Previous Price * 117.30 USD 17.04.2025
52 Week High * 139.34 USD 04.10.2024
52 Week Low * 108.93 USD 09.04.2025
NAV * 120.57 USD 22.04.2025
Issue Price *
Redemption Price *
Closing Price *
Indicative Minimum Price
Fund Assets *** 64,560,256
Unit/Share Assets ***
Trading Information SIX

Performance

YTD Performance +3.53% 30.12.2024
22.04.2025
YTD Performance (in CHF) -5.77% 30.12.2024
22.04.2025
1 month +0.79% 24.03.2025
22.04.2025
3 months +4.84% 22.01.2025
22.04.2025
6 months -8.37% 22.10.2024
22.04.2025
1 year +5.60% 22.04.2024
22.04.2025
2 years -17.67% 24.04.2023
22.04.2025
3 years -17.21% 22.04.2022
22.04.2025
5 years -51.71% 15.06.2021
22.04.2025

Tax Data

Equity Participation Rate in %
Share of Total Fund Assets in %
Real Estate Rate in %
ADDI
ADDI Date

Top 10 Holdings ***

Celltrion Inc 7.04%
Sun Pharmaceuticals Industries Ltd 6.96%
BeiGene Ltd ADR 6.84%
WuXi Biologics (Cayman) Inc 5.13%
Samsung BioLogics Co Ltd 4.50%
Akeso Inc Ordinary Shares 3.63%
Sino Biopharmaceutical Ltd 3.43%
Cipla Ltd 3.33%
Rede d or Sao Luiz SA Ordinary Shares 3.22%
Innovent Biologics Inc 3.12%
Last data update 31.03.2025

Cost / Risk

TER 1.51%
TER date 29.01.2021
Performance Fee *** 0.00%
PTR
Max. Management Fee *** 0.90%
Ongoing Charges *** 1.38%
SRRI ***
SRRI date *** 31.03.2025

Breakdowns

Countries ***

Stock Sectors ***


* NAV / Issue Price exclusive commissions, for listed funds NAV or closing price
** Calculation of interim profit followed § 9 Satz 2 InvStG
*** Data source: Morningstar (Data is based on the rescaled long position of the holdings)